August 9, 2023 06:11 AM EDTUpdated 08:27 AM
R&D

No­var­tis flex­es PhI­II win for oral BTK in­hibitor in chron­ic spon­ta­neous ur­ticaria

Reynald Castañeda

Deputy Editor

No­var­tis re­vealed pos­i­tive news from two Phase III tri­als that are study­ing its oral BTK in­hibitor remi­bru­ti­nib in chron­ic spon­ta­neous ur­ticaria, set­ting up po­ten­tial reg­u­la­to­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times